Sarepta Therapeutics

Elevidys — AAV rh74 micro-dystrophin.

Country: United States
Ticker: SRPT

FDA approved

Coverage

	CN	EU	US
regenerative-personalized	✓	✓	✓
therapeutics-platforms	✓	✓	✓

Regulatorsfdaemanmpa

Verifiable facts

Fact	Value	Source
Founded	1980	umbrex.com
Headquarters	Cambridge, Massachusetts, United States	investorrelations.sarepta.com · umbrex.com
Headcount	approximately 843 to 899 employees (as of 2026)	investorrelations.sarepta.com
Revenue	$1,864.3 million (total net product revenue for 2025); $328.7 million (total net product revenue for Q2 2026)	investorrelations.sarepta.com
Regulatory approval	FDA accelerated approval (June 2023) and traditional/expanded approval (June 2024) for Elevidys in the U.S.; approval in Japan (May 2025)	investorrelations.sarepta.com
Production site	Catalent facilities in Harmans, Maryland (BWI) and Baltimore, Maryland	endpoints.news · investorrelations.sarepta.com
Capacity	Relies on contract manufacturing partners (Catalent and Aldevron); manufacturing capacity and supply chain subject to operational requirements and agreements with partners medium confidence	endpoints.news · investorrelations.sarepta.com · umbrex.com

Independent sources: endpoints.news · investorrelations.sarepta.com · umbrex.com

Technologies

Name	Cluster	Risk
In-vivo gene therapy: AAV and lentiviral vectors	therapeutics-platforms	Medium	→
Nucleic acid therapeutics (oligonucleotides)	therapeutics-platforms	Low	→
Personalized & regenerative medicine	regenerative-personalized	Medium	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.